Table 3.

Clinicopathologic features, treatment, and follow-up data in patients with breast cancer with Li-Fraumeni syndrome

Patient	Age (yr)	Age	Histological type	Grade	Stage	ER	PR	HER2	Surgery	CTX	HTX	RTX	Anti-HER2 therapy
3	24	Right	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Mastectomy	Adjuvant	No	Yes	No
	35	Left	IDC	3	cT2N2a)	Neg	Neg	Pos	Mastectomy	Neoadjuvant	No	Yes	Yes
5	28	Left	DCIS	1	pTisN0	Pos	Pos	Neg	Mastectomy	No	Yes	No	No
6	29	Right	Mucinous carcinoma	2	pT1N0	Pos	Pos	Neg	Mastectomy	Adjuvant	Yes	No	No
7	31	Right	IDC	3	cT2N3a)	Neg	Neg	Pos	BCS	Neoadjuvant	No	Yes	Yes
	34	Left	IDC	2	pT1N0	Pos	Pos	Neg	BCS	No	Yes	Yes	No
8	33	Left	IDC	Unknown	cT1N1a)	Pos	Neg	Pos	Mastectomy	Neoadjuvant	Yes	No	Yes
9	38	Right	IDC	3	cT3N0a)	Pos	Neg	Pos	Mastectomy	Neoadjuvant	Yes	No	Yes
	38	Left	IDC	2	cT2N0a)	Pos	Neg	Neg	Mastectomy	Neoadjuvant	Yes	No	Yes
10	40	Right	DCIS	3	pTisN0	Neg	Neg	Pos	Mastectomy	No	No	No	No
11	43	Left	IDC	Unknown	Unknown	Unknown	Unknown	Unknown	BCS	No	No	Yes	Unknown
12	47	Right	IDC	3	pT2N2	Pos	Pos	Pos	Mastectomy	Adjuvant	Yes	Unknown	Unknown

BCS, breast-conserving surgery; CTX, chemotherapy; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HTX, hormone therapy; IDC, invasive ductal carcinoma; Neg, negative; Pos, positive; PR, progesterone receptor; RTX, radiation therapy.

^a)Clinical stage before neoadjuvant chemotherapy.